Skip to content

Author

Zheng-Liang Li

We have 6 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Emerging Role of Human Long Non-coding RNA HOST2 as a Regulator and Biomarker across Multiple Cancer Types.

Clinically, elevated HOST2 expression has been associated with advanced tumor stage, lymph node or distant metastasis, and unfavorable overall survival in several cancer types, suggesting potential value as a prognostic biomarker and therapeutic target.

Qian-Wen Du, Ling-Yun Zhou, Dan Song et al. · 0 citations
Open access Sep 2026

FANCD2 knockdown suppresses malignant phenotypes and is associated with caspase/PARP-mediated apoptosis in NCI-H2052 pleural mesothelioma cells

Evaluating FANCD2 expression and its clinical associations in PM and the effects of transient FANCD2 knockdown in NCI-H2052 cells demonstrated that FANCD2 was significantly upregulated in PM tissues relative to normal control samples, suggesting that FANCD2 may contribute to PM progression by supporting malignant pheno...

Ying-Fang Xiang, Pu Su, Rui-Ying Zhang et al. · 0 citations
Review Oct 2026

Emerging roles of long non-coding RNA CASC2 in tumor chemoresistance - a review.

Malignant tumors remain a leading cause of global mortality, and the development of chemoresistance represents a major obstacle to effective cancer treatment. Long non-coding RNAs (lncRNAs) are important regulators of tumor progression and therapeutic response. Cancer susceptibility candidate 2 (CASC2) is an lncRNA tha...

Ling-Yun Zhou, Jin-Tao He, Wen-Bing Huang et al. · 0 citations
Review Open access Sep 2026

Long non-coding RNA GAS6-AS1 and its molecular mechanisms in human cancer (Review)

GAS6-AS1 represents a promising molecule for understanding cancer pathogenesis and developing novel strategies for precision cancer diagnosis and treatment, although further clinical validation and mechanistic studies are still required.

Zhi-Ling Lu, Wen-Bing Huang, Jin-Tao He et al. · 0 citations
Aug 2026

ADRB2 Modulates Asbestos-Induced Pleural Mesothelioma Progression by Influencing IL-17/NF-κB-Related Inflammatory Signalling: An Integrated Network Toxicology, Multi-Omics and Experimental Study.

Findings identify ADRB2 as a potential diagnostic and mechanistic target in asbestos-related PM and suggest that ADRB2 may contribute to crocidolite-induced malignant progression by modulating cellular responses associated with IL-17/NF-κB-related inflammatory signalling.

Shaoyang Huang, Dandan Gu, Jin-Tao He et al. · 0 citations
Open access Jul 2026

Integrating network pharmacology, molecular docking, and experimental validation to investigate the therapeutic effects and potential mechanisms of lycopene against pancreatic ductal adenocarcinoma

Preliminary mechanistic evidence is provided for further preclinical investigation of lycopene in PDAC, but its translational application will require optimized formulations, pharmacokinetic validation, and in vivo efficacy studies to overcome its limited bioavailability.

Shaoyang Huang, Dandan Gu, Dan Song et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.